AAMU
KNSA icon

Amundi Asset Management US’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Amundi Asset Management US’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,900
Closed -$125K – 1638
2018
Q3 		$125K Buy
+4,900
New +$95.3K ﹤0.01% 1506

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Amundi Asset Management US's KNSA Position: Q4 2018 in Review

Amundi Asset Management US sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2018, closing a stake of 4,900 shares — an estimated $125K sold.

Amundi Asset Management US first reported a position in KNSA in Q3 2018 and held it in 1 quarter. The position peaked at $125K in Q3 2018. 52 funds tracked by Wall St. Rank hold KNSA as of Q4 2018.

  • Amundi Asset Management US reported no remaining Kiniksa Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 4,900 Kiniksa Pharmaceuticals shares in Q4 2018, an estimated $125K.
  • Amundi Asset Management US first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Kiniksa Pharmaceuticals position peaked at $125K in Q3 2018.
  • 52 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.